Sabari, MD, which focused on the first-line approval of amivantamab (Ami; Rybrevant; Johnson & Johnson) plus lazertinib ...
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...
AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...
12d
Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...
A gene mutation, or change ... Memorial Sloan Kettering Cancer Center: “Lung Cancer Genomic Testing (EGFR, KRAS, ALK).” National Cancer Institute: “Understanding laboratory tests.” ...
The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...
Abbisko Cayman Limited (HK:2256) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ...
The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.
Dizal announces positive pooled data of sunvozertinib in EGFR TKI-resistant NSCLC: Shanghai, China Friday, December 13, 2024, 18:00 Hrs [IST] Dizal, a biopharmaceutical company co ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback